Ghaddab Imen, Briki Raja, Bouguizene Sassi, Khairi Hedi
Service de Gynécologie et d´Obstétrique, Hôpital Universitaire Farhat Hached, Sousse, Tunisie.
Pan Afr Med J. 2020 Jul 13;36:178. doi: 10.11604/pamj.2020.36.178.23916. eCollection 2020.
malignant germ cell tumors of the ovary (TGMO) are rare ovarian tumors. Each histological type can have clinical and therapeutic particularities which it is important to know. The objective was to report and analyze the particularities of the epidemiological, diagnostic, anatomopathological, therapeutic and prognostic data of TGMO in Tunisian context.
this study is a retrospective descriptive and analytical survey carried out at the Gynecology-Obstetrics departments of the CHU FARHAT HACHED in Sousse over a period of 21years collecting all the cases of patients having been treated for TGMO.
a total number of 30 files was eligible for our study. The average age of our patients was 22years. The majority of patients were in a period of genital activity. The reason for the consultation was mainly represented by abdomino-pelvic pain followed by an increase in abdominal volume. Abdominopelvic ultrasound was performed in 80% of our patients showing a suspicious appearance of malignancy in 100% of them. For our patients, 70% were approached by median laparotomy given the tumor volume and only 30% by laparoscopy. 76.7% had conservative treatment. The predominance of stage I was noted while there was no case in stage IV. The overall survival for all stages was 96.7% at 2years and 85.7% at 5years and 75.8% at 10years. The prognostic factors of the TGMOs isolated from our series were the consultation time greater than 6 months, the age greater than 30years, the tumor size greater than 20cm and the tumor stage.
it would be more interesting to bring together the other cases of TGMO diagnosed in other cancer registries in the country in order to establish a national register of rare ovarian tumors.
卵巢恶性生殖细胞肿瘤（TGMO）是罕见的卵巢肿瘤。每种组织学类型都有其临床和治疗特点，了解这些很重要。目的是报告并分析突尼斯背景下TGMO的流行病学、诊断、解剖病理学、治疗及预后数据的特点。
本研究是一项回顾性描述性和分析性调查，在苏塞的法哈特·哈谢德大学医院妇产科进行，为期21年，收集所有接受TGMO治疗的患者病例。
共有30份病例符合我们的研究。我们患者的平均年龄为22岁。大多数患者处于生殖活跃期。就诊原因主要是腹盆腔疼痛，其次是腹部体积增大。80%的患者进行了腹盆腔超声检查，其中100%显示有可疑的恶性外观。对于我们的患者，鉴于肿瘤体积，70%通过正中剖腹术治疗，仅30%通过腹腔镜检查。76.7%接受了保守治疗。注意到I期占优势，而IV期无病例。所有阶段的2年总生存率为96.7%，5年为85.7%，10年为75.8%。从我们的系列中分离出的TGMO的预后因素为就诊时间大于6个月、年龄大于30岁、肿瘤大小大于20cm和肿瘤分期。
将该国其他癌症登记处诊断出的其他TGMO病例汇总起来，以建立一个罕见卵巢肿瘤国家登记册会更有意义。
